Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Shares Sold by Point72 DIFC Ltd

Point72 DIFC Ltd trimmed its holdings in shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) by 84.3% in the third quarter, Holdings Channel reports. The firm owned 1,210 shares of the biotechnology company’s stock after selling 6,503 shares during the period. Point72 DIFC Ltd’s holdings in Arcturus Therapeutics were worth $28,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Price T Rowe Associates Inc. MD increased its position in shares of Arcturus Therapeutics by 5.7% during the first quarter. Price T Rowe Associates Inc. MD now owns 17,004 shares of the biotechnology company’s stock valued at $575,000 after acquiring an additional 922 shares during the last quarter. Sumitomo Mitsui Trust Holdings Inc. raised its position in Arcturus Therapeutics by 22.4% in the second quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 1,563,065 shares of the biotechnology company’s stock valued at $38,061,000 after purchasing an additional 286,546 shares during the period. Hennion & Walsh Asset Management Inc. raised its position in Arcturus Therapeutics by 8.5% in the second quarter. Hennion & Walsh Asset Management Inc. now owns 34,660 shares of the biotechnology company’s stock valued at $844,000 after purchasing an additional 2,730 shares during the period. Bank of New York Mellon Corp lifted its stake in Arcturus Therapeutics by 3.1% during the second quarter. Bank of New York Mellon Corp now owns 119,181 shares of the biotechnology company’s stock worth $2,902,000 after purchasing an additional 3,578 shares in the last quarter. Finally, ARK Investment Management LLC grew its stake in shares of Arcturus Therapeutics by 16.3% in the second quarter. ARK Investment Management LLC now owns 1,964,964 shares of the biotechnology company’s stock valued at $47,847,000 after buying an additional 275,315 shares in the last quarter. 94.54% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on the company. HC Wainwright reissued a “buy” rating and set a $63.00 target price on shares of Arcturus Therapeutics in a research note on Friday, November 8th. Cantor Fitzgerald reissued an “overweight” rating on shares of Arcturus Therapeutics in a research note on Monday, September 9th. Seven research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus price target of $71.40.

Insider Buying and Selling at Arcturus Therapeutics

In other news, COO Pad Chivukula sold 12,000 shares of the stock in a transaction dated Tuesday, October 15th. The stock was sold at an average price of $20.76, for a total value of $249,120.00. Following the transaction, the chief operating officer now owns 435,334 shares in the company, valued at approximately $9,037,533.84. This represents a 2.68 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 15.30% of the stock is owned by insiders.

Arcturus Therapeutics Stock Performance

Shares of Arcturus Therapeutics stock opened at $18.36 on Wednesday. The business has a 50-day simple moving average of $19.33 and a 200-day simple moving average of $22.58. The company has a market cap of $497.37 million, a PE ratio of -8.27 and a beta of 2.62. Arcturus Therapeutics Holdings Inc. has a one year low of $14.93 and a one year high of $45.00.

Arcturus Therapeutics (NASDAQ:ARCT) last announced its quarterly earnings data on Thursday, November 7th. The biotechnology company reported ($0.26) EPS for the quarter, beating analysts’ consensus estimates of ($0.70) by $0.44. The company had revenue of $41.67 million for the quarter, compared to the consensus estimate of $49.16 million. Arcturus Therapeutics had a negative net margin of 36.39% and a negative return on equity of 22.39%. During the same period in the prior year, the firm posted ($0.61) EPS. On average, sell-side analysts predict that Arcturus Therapeutics Holdings Inc. will post -2.31 earnings per share for the current fiscal year.

Arcturus Therapeutics Profile

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.